AEG35156 antisense IV infusion

DRUG2 trials

Sponsors

Aegera Therapeutics

Conditions

Advanced Hepatocellular CarcinomaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell

Phase 1

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

TerminatedNCT00768339

Aegera TherapeuticsLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Start: 2008-09-30End: 2011-09-30Updated: 2011-07-13

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

CompletedNCT00882869

Aegera TherapeuticsAdvanced Hepatocellular Carcinoma

Start: 2009-03-31End: 2011-05-31Target: 75Updated: 2011-07-13